COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 8 FDA records to the applicant name Vascutek, Ltd.. It includes 1 original PMA approval. 3 entries are PMA supplements. 4 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Apr 19, 2022 to Sep 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QSK appears in 8 of the 8 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P210006, with 8 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: Newmains Ave., Inchinnan, PA49RR. Recorded on P210006/S018, decision dated Sep 8, 2026.
Device categories in this collection
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment.
Changes described in PMA records
The FDA's decision for P210006/S018 is an approval of a supplement to the existing Thoraflex Hybrid PMA, filed on the Normal 180 Day Track and categorized as a change to design, components, specifications or material. The source statement describes the purpose as approval for new branch configurations of the device, a hybrid stent graft for thoracic aortic lesion treatment with product code QSK.
The identifier ties S018 to original PMA P210006, so this is a modification within that approval rather than a new approval of the whole system. The record does not specify which branches, their dimensions or materials, or any supporting data; the stated purpose of the change is not evidence of safety or clinical effectiveness.
FDA approval-order wording
approval for new branch configurations of the Thoraflex Hybrid device
Sep 8, 2026 · Normal 180 Day TrackFDA’s recorded scope: updated manufacturing inspections for the endovascular sub-assembly parts of the Thoraflex Hybrid
Jun 24, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for extension of shelf-life to 3-years
Apr 20, 2026 · Real-Time ProcessFDA’s recorded scope: an update to the lFU to include additional language regarding early imaging surveillance for patients at risk for intraluminal thrombosis
Jan 29, 2026 · Special (Immediate Track)FDA’s recorded scope: removal of select incoming inspection steps and select incoming goods bioburden monitoring procedures for the Thoraflex Hybrid device
Oct 29, 2025 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.